To determine whether survival is extended when all MCPs are genetically ablated in both TME and tumor cells, we induced de novo GBM in WT; Ntv-a and qMCP−/−; Ntv-a mice by co-injecting RCAS-shp53 and RCAS-PDGFB in the frontal striatum. This evidence concerns the gene PDGFB and glioblastoma.